NCT05578326View on ClinicalTrials.gov

Study of Trilaciclib and Lurbinectidin

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

December 25, 2025

Study Completion Date

December 25, 2027

Conditions
Lung CancerSmall-cell Lung Cancer
Interventions
DRUG

Trilaciclib

240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle

DRUG

Lurbinectedin

3.2 mg/m2, over 60 minutes at day 1 of each cycle

Trial Locations (2)

27599

RECRUITING

Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill

03756

WITHDRAWN

Dartmouth Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

G1 Therapeutics, Inc.
All Listed Sponsors
collaborator

G1 Therapeutics, Inc.

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER